Dengue Clinical Trial
Official title:
Quantifying the Epidemiological Impact of Targeted Indoor Residual Spraying on Aedes-borne Diseases
Verified date | May 2024 |
Source | Emory University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The trial will be conducted in the city of Merida extending ongoing longitudinal cohort to follow a population of 4,600 children 2-15 years old randomly allocated to receive either TIRS treatment or not. If efficacious, TIRS will drive a paradigm shift in Aedes control by: considering Ae. aegypti behavior to rationally guide insecticide applications; the change to preventive control (pre- ABD transmission season rather than in response to symptomatic cases); the use of third generation insecticides to which Ae. Aegypti is susceptible.
Status | Active, not recruiting |
Enrollment | 4702 |
Est. completion date | December 31, 2024 |
Est. primary completion date | December 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Years to 15 Years |
Eligibility | Inclusion Criteria: 1. Household Level Inclusion Criteria: - Household is located within the bounds of a study cluster (5x5 city-block clusters). - City block has at least 60% premises that are residential. 2. Individual Level Inclusion Criteria: - 2 or more and up to 15 years of age at the time of initial enrollment - Living in a house that consented to TIRS. Exclusion Criteria: 1. Household Level Exclusion Criteria: - Households where study personnel identify a security risk (i.e., site where drugs are sold, residents are always drunk or hostile) - Sites where no residents spend time during the day (i.e. work 7d a week outside the home).Inability for a resident to provide informed consent. - Non-residential places (e.g., businesses, schools, markets, etc.). 2. Individual Level Exclusion Criteria: - Less than 2 years of age or more than 15 years of age at the time of enrollment. - Not living in a house that consented to TIRS. - Having a medical condition that prevents implementation of study procedures. - Temporary visitor to household - Plans to leave study area within next 12 months |
Country | Name | City | State |
---|---|---|---|
Mexico | Universidad Autonoma de Yucatan | Merida | Yucatan |
Lead Sponsor | Collaborator |
---|---|
Emory University | National Institute of Allergy and Infectious Diseases (NIAID) |
Mexico,
Che-Mendoza A, Gonzalez-Olvera G, Medina-Barreiro A, Arisqueta-Chable C, Bibiano-Marin W, Correa-Morales F, Kirstein OD, Manrique-Saide P, Vazquez-Prokopec GM. Efficacy of targeted indoor residual spraying with the pyrrole insecticide chlorfenapyr against pyrethroid-resistant Aedes aegypti. PLoS Negl Trop Dis. 2021 Oct 4;15(10):e0009822. doi: 10.1371/journal.pntd.0009822. eCollection 2021 Oct. — View Citation
Dzib-Florez S, Ponce-Garcia G, Medina-Barreiro A, Gonzalez-Olvera G, Contreras-Perera Y, Del Castillo-Centeno F, Ahmed AMM, Che-Mendoza A, McCall PJ, Vazquez-Prokopec G, Manrique-Saide P. Evaluating Over-the-Counter Household Insecticide Aerosols for Rapid Vector Control of Pyrethroid-Resistant Aedes aegypti. Am J Trop Med Hyg. 2020 Nov;103(5):2108-2112. doi: 10.4269/ajtmh.20-0515. — View Citation
Dzul-Manzanilla F, Correa-Morales F, Che-Mendoza A, Palacio-Vargas J, Sanchez-Tejeda G, Gonzalez-Roldan JF, Lopez-Gatell H, Flores-Suarez AE, Gomez-Dantes H, Coelho GE, da Silva Bezerra HS, Pavia-Ruz N, Lenhart A, Manrique-Saide P, Vazquez-Prokopec GM. Identifying urban hotspots of dengue, chikungunya, and Zika transmission in Mexico to support risk stratification efforts: a spatial analysis. Lancet Planet Health. 2021 May;5(5):e277-e285. doi: 10.1016/S2542-5196(21)00030-9. — View Citation
Kirstein OD, Ayora-Talavera G, Koyoc-Cardena E, Chan Espinoza D, Che-Mendoza A, Cohuo-Rodriguez A, Granja-Perez P, Puerta-Guardo H, Pavia-Ruz N, Dunbar MW, Manrique-Saide P, Vazquez-Prokopec GM. Natural arbovirus infection rate and detectability of indoor female Aedes aegypti from Merida, Yucatan, Mexico. PLoS Negl Trop Dis. 2021 Jan 4;15(1):e0008972. doi: 10.1371/journal.pntd.0008972. eCollection 2021 Jan. — View Citation
Manrique-Saide P, Dean NE, Halloran ME, Longini IM, Collins MH, Waller LA, Gomez-Dantes H, Lenhart A, Hladish TJ, Che-Mendoza A, Kirstein OD, Romer Y, Correa-Morales F, Palacio-Vargas J, Mendez-Vales R, Perez PG, Pavia-Ruz N, Ayora-Talavera G, Vazquez-Prokopec GM. The TIRS trial: protocol for a cluster randomized controlled trial assessing the efficacy of preventive targeted indoor residual spraying to reduce Aedes-borne viral illnesses in Merida, Mexico. Trials. 2020 Oct 8;21(1):839. doi: 10.1186/s13063-020-04780-7. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of laboratory confirmed (RT-PCR or IgM/IgG ELISA) symptomatic Aedes-borne Viruses in paired acute and convalescent samples living in the core 3x3 city blocks of each cluster. | Number of laboratory confirmed (RT-PCR or IgM/IgG ELISA) symptomatic Aedes-borne Viruses (DENV, CHIKV and ZIKV) in paired acute and convalescent samples for a subset of children living in the core 3x3 city blocks of the cluster. | Up to 5 years | |
Secondary | Number of laboratory confirmed (IgG ELISA and neutralization testing) Aedes-borne Viruses cases in annual surveillance samples | Number of laboratory confirmed (IgG ELISA and neutralization testing) Aedes-borne Viruses (DENV, CHIKV and ZIKV) in annual surveillance samples | Up to 5 years | |
Secondary | Ae. aegypti mosquito infection rate with Aedes-borne Viruses (DENV, CHIKV and ZIKV) | Ae. aegypti mosquito infection rate with Aedes-borne Viruses (DENV, CHIKV and ZIKV) assessed by RT-PCR | Up to 5 years | |
Secondary | Ae. aegypti indoor entomological index adult presence/abundance | Ae. aegypti indoor entomological index adult presence/abundance will be calculated. Presence of mosquitoes/house. The higher the value, the worst the outcome. | Up to 5 years | |
Secondary | Ae. aegypti indoor entomological index female presence/abundance | Ae. aegypti indoor entomological index female presence/abundance will be calculated. Number of mosquitoes/house. The higher the value, the worst the outcome. | Up to 5 years | |
Secondary | Ae. aegypti indoor entomological index bloodfed female presence/abundance. Number of bloodfed females per house. The higher the value, the works the outcome. | Ae. aegypti indoor entomological index bloodfed female presence/abundance will be calculated | Up to 5 years | |
Secondary | Number of laboratory confirmed (RT-PCR or IgM/IgG ELISA) symptomatic Aedes-borne Viruses in paired acute and convalescent samples living in the entire cluster. | Number of laboratory confirmed (RT-PCR or IgM/IgG ELISA) symptomatic Aedes-borne Viruses (DENV, CHIKV and ZIKV) in paired acute and convalescent samples for a subset of children living in the entire cluster. | Up to 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05321264 -
Educational Intervention to Promote Control Behaviors and Prevention of Dengue
|
N/A | |
Completed |
NCT01436396 -
Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers
|
Phase 3 | |
Completed |
NCT01391819 -
Study to Evaluate the Incidence, Clinical Characteristics and Economic Burden of Dengue in Brazilian Children
|
N/A | |
Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
Completed |
NCT02833584 -
Safety of Paracetamol as Antipyretic in Treatment of Dengue Infection in Adults
|
N/A | |
Completed |
NCT02433652 -
Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2
|
Phase 1 | |
Enrolling by invitation |
NCT02016027 -
Pharmacological Effect of Carica Papaya Leaves Mother Tincture in Healthy Individuals Blood Parameter
|
Phase 1 | |
Completed |
NCT01477671 -
Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children
|
N/A | |
Recruiting |
NCT00377754 -
Prospective Study of Infant Dengue
|
N/A | |
Recruiting |
NCT05919277 -
A Dengue Sero-prevalence Study in the Metropolitan Area of Buenos Aires
|
||
Recruiting |
NCT04582474 -
Demonstration of an Electronic Clinical Decision Support Module for Dengue in Burkina Faso
|
N/A | |
Completed |
NCT01983553 -
Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study
|
||
Completed |
NCT03803618 -
Dengue Effectiveness Study in the Philippines
|
||
Active, not recruiting |
NCT05967455 -
Homologous Re-infection With Dengue 1 or Dengue 3
|
Phase 1 | |
Completed |
NCT03631719 -
Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia
|
||
Recruiting |
NCT02606019 -
The Use of Biomarkers in Predicting Dengue Outcome
|
N/A | |
Completed |
NCT02372175 -
Assessment of a Dengue-1-Virus-Live Virus Human Challenge - (DENV-1-LVHC) Virus Strain
|
Phase 1 | |
Active, not recruiting |
NCT01696422 -
Phase II Trial to Evaluate Safety and Immunogenicity of a Dengue 1,2,3,4 (Attenuated) Vaccine
|
Phase 2 | |
Completed |
NCT00993447 -
Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America
|
Phase 2 | |
Completed |
NCT00375726 -
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy Adults
|
Phase 1 |